Unilateral GPi vs Unilateral STN DBS in the Same Patient With PD
Unilateral Pallidal vs Unilateral Subthalamic Nucleus Deep Brain Stimulation in the Same Patient With Parkinson Disease: A Randomized Controlled Trial
The subthalamic nucleus (STN) and globus pallidus interna (GPi) are two main targets in the deep brain stimulation (DBS) treatment for Parkinson's disease (PD). Large randomized controlled trials, in which patients of comparable clinical and demographics were randomized to either GPi DBS or STN DBS, have demonstrated equal effects of both targets in motor symptom improvement, the superiority of STN DBS in the medication reduction and the potential advantage of GPi DBS for cognitive, psychiatric and axial aspects. Unfortunately, in such a highly heterogeneous disease of PD, many of these randomized controlled trials didn't include sufficient subjects and thereby yielded inconsistent results. Moreover, most studies are investigating the difference between GPi and STN in different patients.
In order to address the problem, an intra-patient comparison will be made by investigating the acute turning-on effects of unilateral STN stimulation versus unilateral GPi stimulation on axial symptoms, cognition and also cardinal symptoms within each individual patient who received the treatment of combined unilateral STN and contralateral GPi DBS. Axial symptoms including gait, balance and posture, motor symptoms and cognition are comprehensively assessed under two treatment conditions.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Shanghai
-
Shanghai、Shanghai、中国、200025
- Functional neurosurgery of Shanghai Jiaotong University affiliated Ruijin Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with idiopathic Parkinson's disease
- Aged between 55 and 75 years, both male and female
- Patients who have undergone combined unilateral STN and contralateral GPi DBS for more than 6 months
- A Hoehn-Yahr (H-Y) stage of less than 4 in the off-medication state
- A left-extremity to right-extremity ratio of less than 0.15 on the Unified Parkinson's Disease Rating Scale part Ⅲ (UPDRS-Ⅲ) in the both off-medication and on-medication states
Exclusion Criteria:
- History of serious psychosis
- History of intractable epilepsy (i.e., seizures)
- Diagnosed by the investigators that patients with severe cardiac, liver and kidney diseases, or other serious health conditions
- Dementia (A Mini-Mental State Examination (MMSE) score of < 24), inability to comprehend the experimental protocol or voluntarily provide informed consent
- Lack of cooperation
- Additional reasons for exclusion at the discretion of the clinical investigator
- Poorly controlled depression or anxiety
- Past history of suicidal attempt
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Unilateral DBS of the subthalamic nucleus (STN)
To deliver unilateral STN DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral STN DBS.
The STN stimulation will be programmed as previous parameter configuration with optimal therapeutic benefits.
Participants will be asked to complete a comprehensive set of assessments under unilateral STN stimulation in the off-medication state.
45 minutes after taking regular medication, participants need to complete the second set of assessments in the on-medication state.
|
Unilateral DBS for treatment of patients with PD
|
|
実験的:Unilateral DBS of the globus pallidus interna (GPi)
To deliver unilateral GPi DBS, bilateral stimulation will be turned off for three hours, and then turn on the unilateral GPi DBS.
The study protocol is identical to the intervention of unilateral STN DBS but it was done on a different day.
|
Unilateral DBS for treatment of patients with PD
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference in Timed Up-and-Go (TUG) task scores between treatment conditions in the on- and off- medication states
時間枠:6 months
|
Timed Up-and-Go task is a well-defined objective gait measurement.
The task requires an individual to stand up, walk 5 m, turn, walk back, and sit down.
The time taken to complete the test is strongly correlated with the level of functional mobility.
This test will be videotaped and scored by two blinded neurologists.
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Differences in total Unified Parkinson's Disease Rating Scale Part Ⅲ (UPDRS Ⅲ) scores between two treatment conditions in the on- and off- medication states
時間枠:6 months
|
Unified Parkinson's Disease Rating Scale Part Ⅲ measures the motor severity of Parkinson's disease.
UPDRS Ⅲ score has a range of 0 (no symptoms) to 132 (severe disease symptoms).
|
6 months
|
|
Differences in Burg Balance Scale (BBS) scores between two treatment conditions in the on- and off- medication states.
時間枠:6 months
|
Burg Balance Scale measures patients' static and dynamic balance abilities.
BBS score has a range of 0 (severe balance problems) to 56 (no balance problems).
|
6 months
|
|
Differences in postural angles between two treatment conditions in the on- and off- medication states.
時間枠:6 months
|
The measurement of postural angles is the same as the paper (Yamada et al) published in J Neurol Neurosurg Psychiatry
|
6 months
|
|
Differences in Water Swallow Test (WST) scores between treatment conditions in the on- and off- medication states.
時間枠:6 months
|
The Water Swallow Test is frequently used in clinical practice as a functional assessment to detect dysphagia, with stage 1 indicating severe dysphagia and stage 6 indicating normal swallowing function.
|
6 months
|
|
Differences in Swallowing Disturbance Questionnaire (SDQ) scores between treatment conditions in the on- and off- medication states.
時間枠:6 months
|
The Swallowing Disturbance Questionnaire is created as a self-rated dysphagia screening tool in PD, with a range of 0 (normal swallowing function) to 42 (severe dysphagia).
|
6 months
|
|
Differences in voice parameters between treatment conditions in the on- and off- medication states.
時間枠:6 months
|
Voice recording at a sampling rate of 44.1 kHz using 16-bit quantification will be conducted in a sound-treated room using a microphone and a digital voice recorder with a mouth-to-microphone distance of 15 cm.
The recorded voices will then be used for a composit acoustic analysis.
|
6 months
|
|
Differences in Voice Handicap Index (VHI) between treatment conditions in the on- and off- medication states.
時間枠:6 months
|
The Voice Handicap Index is a self-administered instrument, comprising 30 items on voice-related dysfunction.
VHI has a range of 0 (normal voice function) to 120 (severe voice dysfunction).
|
6 months
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Lizarraga KJ, Luca CC, De Salles A, Gorgulho A, Lang AE, Fasano A. Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. Surg Neurol Int. 2017 Oct 24;8:261. doi: 10.4103/sni.sni_292_17. eCollection 2017.
- Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Subthalamic nucleus stimulation improves Parkinson's disease-associated camptocormia in parallel to its preoperative levodopa responsiveness. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):703-9. doi: 10.1136/jnnp-2015-310926. Epub 2015 Sep 30.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。